spacer
home > ict > winter 2017 > up and coming
PUBLICATIONS
International Clinical Trials

Up and Coming

In Sub-Saharan Africa, South Africa remains the optimal location for trials. It accounts for approximately 58% of the total clinical studies conducted within the region and continues to operate as a regional hub. South Africa’s regulatory framework and relatively high level of healthcare infrastructure and public health system make it attractive for trials (1).

The majority of trials that take place in Sub-Saharan Africa are grant-funded and focus on infectious diseases such as HIV, tuberculosis (TB) and malaria. Countries like Burkina Faso, Ghana, Kenya, Malawi, Mali and Tanzania are emerging as viable locations. Both pharmaceutical companies and CROs have been expanding their presence throughout Kenya in the east and Ghana in the west, whereas Nigeria is emerging as a satellite hub to support the growth of clinical trials in this region. Efforts should be taken to harmonise regulatory protocols for the conduct of studies across the continent as most of the guidelines currently vary from country to country.

Development Opportunities

To promote the conduct of clinical research in the region, the Pan African Clinical Trials Registry (PACTR) was established by the South African Cochrane Centre in collaboration with the European and Developing Countries Clinical Trials Partnership and the Cochrane Infectious Disease Group. It is an official registry affiliated with the WHO Network of Primary Registers. The PACTR also provides data to the central WHO International Clinical Trials Registry Platform, so that studies listed in the archive are available through a global platform (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Saravanan Thangaraj is a Senior Research Analyst in the Transformational Health group at Frost & Sullivan. He has over three years of experience in management consulting, has advised clients on strategy and business and has also authored many off-the-shelf industry insight reports during his time at the company. Saravanan’s experience includes biotechnology, pharma, life sciences, in vitro diagnostic devices and health systems. He holds a Bachelor of Technology in Biotechnology and a Master of Business Administration from PSG College of Technology, India.
spacer
Saravanan Thangaraj
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT’s At-Home Cardiac Safety Assessment Ensures Clinical Trial Continuity

PHILADELPHIA – March 30, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a cardiac safety solution that helps biopharmaceutical researchers continue important clinical trials during current global ‘stay home’ mandates. The solution enables clinician-administered ECG readings ─ using ERT’s provisioned, FDA-cleared devices or other investigative site–owned equipment ─ to evaluate the safety of new vaccines and medical treatments from patients’ homes.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement